Home/VenoStent/Pamela Misajon
PM

Pamela Misajon

Chief Compliance Officer

VenoStent

Therapeutic Areas

VenoStent Pipeline

DrugIndicationPhase
SelfWrapImprovement of arteriovenous (AV) access site maturation and patency for hemodialysisPivotal Trial